Insilico Medicine Inc. has identified new glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of atherosclerosis, coronary heart diseases, dementia, diabetes, hypertension, obesity, hyperlipidemia and cerebral infarction.
Haisco Pharmaceutical Group Co. Ltd. has synthesized new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of inflammatory bowel disease and psoriasis.
Augustine Therapeutics NV has divulged thiomethyl carbonyl compounds acting as histone deacetylase 6 (HDAC6) and/or HDAC1 and/or HDAC3 inhibitors. They are reported to be useful for the treatment of inflammatory disorders, autoimmune disease, cancer, neurodegeneration, pain, neuropathy, psychiatric and cardiovascular disorders.
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly patented new potassium voltage-gated channel subfamily A member 3 (KCNA3; Kv1.3) blockers for use in the treatment of autoimmune diseases.
Asieris Pharmaceuticals Co. Ltd. and Shanghai Yahong Meditech Co. Ltd. have discovered new poly(ADP-ribose) glycohydrolase (PARG) inhibitors potentially useful for the treatment of cancer.
Brise Pharmaceutical (Shanghai) Co. Ltd. has discovered carbocyclic or heterocyclic derivatives acting as transient receptor potential cation channel subfamily M member 3 (TRPM3) antagonists.
Apmonia Therapeutics SAS, the Centre National de la Recherche Scientifique and the Université de Reims Champagne Ardenne have disclosed LRP1-derived polypeptides acting as cathepsin D (CTSD) inhibitors.
Work at Emcure Pharmaceuticals Ltd. and Peptris Technologies has led to the identification of new fused bicyclic heterocyclic derivatives acting as histone deacetylase (HDAC) inhibitors.
RSS